Impact of Obesity-Related Inflammation on Cardiac Metabolism and Function

키워드

참고문헌 (111)

1. Finucane MM, "National, regional, and global trends in body-mass index since 1980 : systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants", Lancet, 377, pp.557~567 (2011)
2. World Health Organization, "World health statistics 2016 : monitoring health for the SDGs", World Health Organization, ~ (2016)
3. Zhang X, "Geographic variation in prevalence of adult obesity in China : results from the 2013–2014 national chronic disease and risk factor surveillance", Ann Intern Med, 172, pp.291~293 (2020)
4. Gregor MF, "Inflammatory mechanisms in obesity", Annu Rev Immunol, 29, pp.415~445 (2011)
5. Larsen TS, "Seasonal changes in lipogenesis and lipolysis in isolated adipocytes from Svalbard and Norwegian reindeer", Acta Physiol Scand, 123, pp.97~104 (1985)
6. Gesta S, "Developmental origin of fat : tracking obesity to its source", Cell, 131, pp.242~256 (2007)
7. Item F, "Visceral fat and metabolic inflammation : the portal theory revisited", Obes Rev, 13(Suppl 2), pp.30~39 (2012)
8. Knebel B, "Novel insights into the adipokinome of obese and obese", diabetic mouse models, 2017, pp.18, 1928~
9. Choe SS, "Adipose tissue remodeling: its role in energy metabolism and metabolic disorders", Front Endocrinol(Lausanne), 7, pp.30~ (2016)
10. Longo M, "Adipose tissue dysfunction as determinant of obesity-associated metabolic complications", Int J Mol Sci, 20, pp.2358~ (2019)
11. Shoelson SE, "Inflammation and insulin resistance", J Clin Invest, 116, pp.1793~1801 (2006)
12. Höper AC, "Oil from the marine zooplankton Calanus finmarchicus improves the cardiometabolic phenotype of diet-induced obese mice", Br J Nutr, 110, pp.2186~2193 (2013)
13. Höper AC, "Wax esters from the marine copepod Calanus finmarchicus reduce diet-induced obesity and obesity-related metabolic disorders in mice", J Nutr, 144, pp.164~169 (2014)
14. Hotamisligil GS, "Inflammation and metabolic disorders", Nature, 444, pp.860~867 (2006)
15. Schenk S, "Insulin sensitivity : modulation by nutrients and inflammation", J Clin Invest, 118, pp.2992~3002 (2008)
16. Cinti S, "Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans", J Lipid Res, 46, pp.2347~2355 (2005)
17. Sun K, "Fibrosis and adipose tissue dysfunction", Cell Metab, 18, pp.470~477 (2013)
18. Kim KH, "Autophagy as a crosstalk mediator of metabolic organs in regulation of energy metabolism", Rev Endocr Metab Disord, 15, pp.11~20 (2014)
19. Panee J, "Monocyte chemoattractant protein 1(MCP-1)in obesity and diabetes", Cytokine, 60, pp.1~12 (2012)
20. Chawla A, "Macrophage-mediated inflammation in metabolic disease", Nat Rev Immunol, 11, pp.738~749 (2011)
21. Sun K, "Adipose tissue remodeling and obesity", J Clin Invest, 121, pp.2094~2101 (2011)
22. Solinas G, "JNK1 and IKKbeta : molecular links between obesity and metabolic dysfunction", FASEB J, 24, pp.2596~2611 (2010)
23. Marcus Y, "Adipose tissue renin-angiotensin-aldosterone system(RAAS)and progression of insulin resistance", Mol Cell Endocrinol, 378, pp.1~14 (2013)
24. Makki K, "Adipose tissue in obesity-related inflammation and insulin resistance : cells, cytokines, and chemokines", ISRN Inflamm, 2013, pp.139239~ (2013)
25. Ko HJ, "Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart", Diabetes, 58, pp.2536~2546 (2009)
26. du Toit EF, "Insulin resistance", pp.189~ (2012), IntechOpen
27. Koonen DP, "Long-chain fatty acid uptake and FAT", CD36 translocation in heart and skeletal muscle, 2005, pp.1736, 163~180
28. Luiken JJ, "Regulation of cardiac longchain fatty acid and glucose uptake by translocation of substrate transporters", Pflugers Arch, 448, pp.1~15 (2004)
29. Bonen A, "Regulation of fatty acid transport and membrane transporters in health and disease", Mol Cell Biochem, 239, pp.181~192 (2002)
30. Unger RH, "Lipotoxic diseases", Annu Rev Med, 53, pp.319~336 (2002)
31. Chess DJ, "Role of diet and fuel overabundance in the development and progression of heart failure", Cardiovasc Res, 79, pp.269~278 (2008)
32. Yu C, "Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1(IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle", J Biol Chem, 277, pp.50230~50236 (2002)
33. Wang X, "Insulin resistance accelerates muscle protein degradation : activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling", Endocrinology, 147, pp.4160~4168 (2006)
34. Zhang L, "Role of fatty acid uptake and fatty acid betaoxidation in mediating insulin resistance in heart and skeletal muscle", Biochim Biophys Acta, 1801, pp.1~22 (2010)
35. van Herpen NA, "Lipid accumulation in non-adipose tissue and lipotoxicity", Physiol Behav, 94, pp.231~241 (2008)
36. van den Brom CE, "Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats : studies using positron emission tomography", Cardiovasc Diabetol, 8, pp.39~ (2009)
37. Glenn DJ, "A murine model of isolated cardiac steatosis leads to cardiomyopathy", Hypertension, 57, pp.216~222 (2011)
38. Zhou YT, "Lipotoxic heart disease in obese rats : implications for human obesity", Proc Natl Acad Sci U S A, 97, pp.1784~1789 (2000)
39. Buchanan J, "Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity", Endocrinology, 146, pp.5341~5349 (2005)
40. Carroll JF, "Cardiovascular function in a rat model of diet-induced obesity", Hypertension, 48, pp.65~72 (2006)
41. Sun X, "High free fatty acids level related with cardiac dysfunction in obese rats", Diabetes Res Clin Pract, 95, pp.251~259 (2012)
42. Furuhashi M, "Fatty acid-binding proteins : role in metabolic diseases and potential as drug targets", Nat Rev Drug Discov, 7, pp.489~503 (2008)
43. Zhang J, "Cardiomyocyte overexpression of FABP4aggravates pressure overload-induced heart hypertrophy", PLoS One, 11, pp.e0157372~ (2016)
44. Yagyu H, "Lipoprotein lipase(LpL)on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy", J Clin Invest, 111, pp.419~426 (2003)
45. Kim J, "Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy", Mol Endocrinol, 22, pp.2531~2543 (2008)
46. Shiojima I, "Akt signaling mediates postnatal heart growth in response to insulin and nutritional status", J Biol Chem, 277, pp.37670~37677 (2002)
47. Leopold JA, "Obesity-related cardiomyopathy is an adipocyte-mediated paracrine disease", Trends Cardiovasc Med, 25, pp.127~128 (2015)
48. Blomstrand P, "Overweight and obesity impair left ventricular systolic function as measured by left ventricular ejection fraction and global longitudinal strain", Cardiovasc Diabetol, 17, pp.113~ (2018)
49. Mouton AJ, "Obesity, hypertension, and cardiac dysfunction : novel roles of immunometabolism in macrophage activation and inflammation", Circ Res, 126, pp.789~806 (2020)
50. Pascual M, "Effects of isolated obesity on systolic and diastolic left ventricular function", Heart, 89, pp.1152~1156 (2003)
51. Aasum E, "Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db", db mice, 2003, pp.52, 434~441
52. Belke DD, "Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic(db", db)mice, 2000, pp.279, E1104~E1113
53. Hafstad AD, "High-and moderate-intensity training normalizes ventricular function and mechanoenergetics in mice with diet-induced obesity", Diabetes, 62, pp.2287~2294 (2013)
54. Galderisi M, "Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy(the Framingham Heart Study)", Am J Cardiol, 68, pp.85~89 (1991)
55. Rijzewijk LJ, "Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy : studies with cardiac positron emission tomography and magnetic resonance imaging", J Am Coll Cardiol, 54, pp.1524~1532 (2009)
56. Paulus WJ, "A novel paradigm for heart failure with preserved ejection fraction : comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation", J Am Coll Cardiol, 62, pp.263~271 (2013)
57. Opie LH, "Metabolism of the heart in health and disease. II", Am Heart J, 77, pp.100~122 (1969)
58. Ormazabal V, "Association between insulin resistance and the development of cardiovascular disease", Cardiovasc Diabetol, 17, pp.122~ (2018)
59. Randle PJ, "The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus", Lancet, 1, pp.785~789 (1963)
60. Chanda D, "Signaling pathways involved in cardiac energy metabolism", FEBS Lett, 590, pp.2364~2374 (2016)
61. Glatz JF, "Dynamic role of the transmembrane glycoprotein CD36(SR-B2)in cellular fatty acid uptake and utilization", J Lipid Res, 59, pp.1084~1093 (2018)
62. Mjos OD, "Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs", J Clin Invest, 50, pp.1386~1389 (1971)
63. Peterson LR, "Impact of gender on the myocardial metabolic response to obesity", JACC Cardiovasc Imaging, 1, pp.424~433 (2008)
64. Borst P, "Uncoupling activity of long-chain fatty acids", Biochim Biophys Acta, 62, pp.509~518 (1962)
65. Lopaschuk GD, "Myocardial fatty acid metabolism in health and disease", Physiol Rev, 90, pp.207~258 (2010)
66. Tada M, "Phosphorylation of the sarcoplasmic reticulum and sarcolemma", Annu Rev Physiol, 44, pp.401~423 (1982)
67. Taegtmeyer H, "Linking gene expression to function : metabolic flexibility in the normal and diseased heart", Ann N Y Acad Sci, 1015, pp.202~213 (2004)
68. Scheuermann-Freestone M, "Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes", Circulation, 107, pp.3040~3046 (2003)
69. Rider OJ, "Effects of catecholamine stress on diastolic function and myocardial energetics in obesity", Circulation, 125, pp.1511~1519 (2012)
70. Levelt E, "Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus", Eur Heart J, 37, pp.3461~3469 (2016)
71. Bakermans AJ, "Human cardiac 31PMR spectroscopy at 3 Tesla cannot detect failing myocardial energy homeostasis during exercise", Front Physiol, 8, pp.939~ (2017)
72. Suga H, "Total mechanical energy of a ventricle model and cardiac oxygen consumption", Am J Physiol, 236, pp.H498~H505 (1979)
73. Korvald C, "Myocardial substrate metabolism influences left ventricular energetics in vivo", Am J Physiol Heart Circ Physiol, 278, pp.H1345~H1351 (2000)
74. How OJ, "Influence of substrate supply on cardiac efficiency, as measured by pressure-volume analysis in ex vivo mouse hearts", Am J Physiol Heart Circ Physiol, 288, pp.H2979~H2985 (2005)
75. Cole MA, "A high fat diet increases mitochondrial fatty acid oxidation and uncoupling to decrease efficiency in rat heart", Basic Res Cardiol, 106, pp.447~457 (2011)
76. Carley AN, "Mechanisms responsible for enhanced fatty acid utilization by perfused hearts from type 2 diabetic db", db mice, 2007, pp.113, 65~75
77. Neitzel AS, "Chylomicron and palmitate metabolism by perfused hearts from diabetic mice", Am J Physiol Endocrinol Metab, 284, pp.E357~E365 (2003)
78. Aasum E, "Cardiac function and metabolism in type 2 diabetic mice after treatment with BM 17. 0744, a novel PPAR-α activator", Am J Physiol Heart Circ Physiol, 283, pp.H949~H957 (2002)
79. How OJ, "Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice", Diabetes, 55, pp.466~473 (2006)
80. Hafstad AD, "Glucose and insulin improve cardiac efficiency and postischemic functional recovery in perfused hearts from type 2 diabetic(db", db)mice, 2007, pp.292, E1288~E1294
81. Devereux RB, "Impact of diabetes on cardiac structure and function : the strong heart study", Circulation, 101, pp.2271~2276 (2000)
82. Zhang HS, "Salvianolic acid B from Salvia miltiorrhiza inhibits tumor necrosis factor-alpha(TNF-alpha)-induced MMP-2 upregulation in human aortic smooth muscle cells via suppression of NAD(P)H oxidase-derived reactive oxygen species", J Mol Cell Cardiol, 41, pp.138~148 (2006)
83. Fukuda M, "Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice", J Hypertens, 28, pp.340~352 (2010)
84. Van Linthout S, "Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy", Basic Res Cardiol, 103, pp.319~327 (2008)
85. Park SY, "Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver", Diabetes, 54, pp.2514~2524 (2005)
86. i transient decrease in cardiomyopathy of db, "db type 2 diabetic mice", Diabetes, 55, pp.608~615 (2006)
87. Boudina S, "Diabetic cardiomyopathy revisited", Circulation, 115, pp.3213~3223 (2007)
88. Belke DD, "Altered cardiac calcium handling in diabetes", Curr Hypertens Rep, 6, pp.424~429 (2004)
89. Stølen TO, "Interval training normalizes cardiomyocyte function, diastolic Ca2+ control, and SR Ca2+ release synchronicity in a mouse model of diabetic cardiomyopathy", Circ Res, 105, pp.527~536 (2009)
90. Peterson LR, "Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women", Circulation, 109, pp.2191~2196 (2004)
91. Boardman N, "Increased O2 cost of basal metabolism and excitation-contraction coupling in hearts from type 2 diabetic mice", Am J Physiol Heart Circ Physiol, 296, pp.H1373~H1379 (2009)
92. Look AHEAD Research Group, "Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study", Obesity (Silver Spring), 22, pp.5~13 (2014)
93. Van Gaal L, "Pharmacological approaches in the treatment and maintenance of weight loss", Diabetes Care, 39(Suppl 2), pp.S260~S267 (2016)
94. Devenny JJ, "Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese(DIO)rats", Obesity(Silver Spring), 20, pp.1645~1652 (2012)
95. Stenlöf K, "Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise", Diabetes Obes Metab, 15, pp.372~382 (2013)
96. Crane J, "The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity", Ther Adv Chronic Dis, 7, pp.92~107 (2016)
97. Mancini MC, "The burden of obesity in the current world and the new treatments available : focus on liraglutide 3. 0 mg", Diabetol Metab Syndr, 9, pp.44~ (2017)
98. Simopoulos AP, "Omega-3 fatty acids in health and disease and in growth and development", Am J Clin Nutr, 54, pp.438~463 (1991)
99. Itariu BK, "Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients : a randomized controlled trial", Am J Clin Nutr, 96, pp.1137~1149 (2012)
100. Hu Y, "Marine omega-3 supplementation and cardiovascular disease : an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants", J Am Heart Assoc, 8, pp.e013543~ (2019)
101. Rimm EB, "Seafood long-chain n-3polyunsaturated fatty acids and cardiovascular disease : a science advisory from the American Heart Association", Circulation, 138, pp.e35~e47 (2018)
102. Natto ZS, "Omega-3 fatty acids effects on inflammatory biomarkers and lipid profiles among diabetic and cardiovascular disease patients : a systematic review and meta-analysis", Sci Rep, 9, pp.18867~18867 (2019)
103. Buoite Stella A, "Update on the impact of omega 3 fatty acids on inflammation, insulin resistance and sarcopenia : a review", Int J Mol Sci, 19, pp.218~ (2018)
104. El-Bayoumy K, "Customized prevention trials could resolve the controversy of the effects of omega-3 fatty acids on cancer", Nutr Cancer, 72, pp.183~186 (2020)
105. Calder PC, "Marine omega-3 fatty acids and inflammatory processes : effects, mechanisms and clinical relevance", Biochim Biophys Acta, 1851, pp.469~484 (2015)
106. Jansen KM, "Dietary Calanus oil recovers metabolic flexibility and rescues postischemic cardiac function in obese female mice", Am J Physiol Heart Circ Physiol, 317, pp.H290~ (2019)
107. Rustan AC, "Dietary supplementation of very long-chain n-3 fatty acids decreases whole body lipid utilization in the rat", J Lipid Res, 34, pp.1299~1309 (1993)
108. Edland F, "Long-term consumption of an obesogenic high fat diet prior to ischemia-reperfusion mediates cardioprotection via Epac1-dependent signaling", Nutr Metab(Lond), 13, pp.87~ (2016)
109. Grove KL, "A microarray analysis of sexual dimorphism of adipose tissues in high-fat-diet-induced obese mice", Int J Obes, 34, pp.989~1000 (2010)
110. Wasserfurth P, "Effects of exercise combined with a healthy diet or Calanus finmarchicus oil supplementation on body composition and metabolic markers-a pilot study", Nutrients, 12, pp.2139~ (2020)
111. Wasserfurth P, "Intake of Calanus finmarchicus oil for 12 weeks improves omega-3 index in healthy older subjects engaging in an exercise programme", Br J Nutr, pp.1~8 (2020)

관련 논문AI추천